

Status: Currently Official on 15-Feb-2025  
 Official Date: Official as of 01-Aug-2024  
 Document Type: USP Monographs  
 DocId: GUID-D5D9EEE9-ADE7-4D1B-B568-DC0AD179C932\_5\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M46470\\_05\\_01](https://doi.org/10.31003/USPNF_M46470_05_01)  
 DOI Ref: p3mdl

© 2025 USPC  
 Do not distribute

## Magaldrate and Simethicone Oral Suspension

» Magaldrate and Simethicone Oral Suspension contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of magaldrate  $[Al_5Mg_{10}(OH)_{31}(SO_4)_2]$ , and an amount of polydimethylsiloxane  $[-(CH_3)_2SiO-]_n$  that is not less than 85.0 percent and not more than 115.0 percent of the labeled amount of simethicone.

**Packaging and storage**—Preserve in tight containers, and keep from freezing.

**USP REFERENCE STANDARDS (11)**—

[USP Magaldrate RS](#)

[USP Polydimethylsiloxane RS](#)

**Identification**—

**A:** Dissolve an amount of Oral Suspension, equivalent to about 800 mg of magaldrate, in 20 mL of 3 N hydrochloric acid, dilute with water to about 50 mL, add 3 drops of methyl red TS, and proceed as directed in *Identification* test A under [Magaldrate](#), beginning with “and heat to boiling.”

**B:** Wash the precipitate obtained in [Identification](#) test A with hot ammonium chloride solution (1 in 50), and dissolve the precipitate in hydrochloric acid. Divide this solution into two portions: the dropwise addition of 6 N ammonium hydroxide to one portion yields a gelatinous white precipitate, which does not dissolve in an excess of 6 N ammonium hydroxide. The dropwise addition of 1 N sodium hydroxide to the other portion yields a gelatinous white precipitate, which dissolves in an excess of 1 N sodium hydroxide, leaving some turbidity.

**C:** Transfer an amount of Oral Suspension, equivalent to about 1 g of magaldrate, to a 100-mL centrifuge tube. Add about 60 mL of water, insert the cap, and shake for 3 minutes. Centrifuge the suspension, and discard the supernatant. Repeat the washing of the residue with three 60-mL portions of water. Transfer the residue to a 250-mL beaker, and heat on a steam bath to dryness: the X-ray diffraction pattern (see [X-Ray Powder Diffraction \(941\)](#)), in the d-spacings region below 2.57 angstrom units, of the residue so obtained conforms to that of [USP Magaldrate RS](#).

**D:** The IR absorption spectrum, in the 7- to 15- $\mu$ m region, determined in a 0.1-mm cell, of the *Assay preparation* prepared as directed in the [Assay for polydimethylsiloxane](#) exhibits maxima only at the same wavelengths as that of the *Standard preparation* prepared as directed in the [Assay for polydimethylsiloxane](#).

**MICROBIAL ENUMERATION TESTS (61) and TESTS FOR SPECIFIED MICROORGANISMS (62)**—Its total aerobic microbial count does not exceed 100 cfu per mL, and it meets the requirements of the test for absence of *Escherichia coli*.

**ACID-NEUTRALIZING CAPACITY (301)**—The acid consumed by the minimum single dose recommended in the labeling is not less than 5 mEq, and not less than the number of mEq calculated by the formula:

$$0.8(0.0282M)$$

in which 0.0282 is the theoretical acid-neutralizing capacity, in mEq per mg, of magaldrate; and *M* is the quantity, in mg, of the labeled amount of magaldrate.

**Magnesium hydroxide content**—

*Test preparation*—Transfer an accurately measured quantity of Oral Suspension, equivalent to about 1 g of magaldrate, to a 100-mL volumetric flask, add 30 mL of dilute hydrochloric acid (1 in 10), shake to dissolve, dilute with water to volume, and mix.

*Procedure*—Transfer 10.0 mL of *Test preparation* to a 400-mL beaker, and proceed as directed in the test for [Magnesium hydroxide content](#) under [Magaldrate](#), beginning with “and dilute with water to about 200 mL.” Not less than 492 mg and not more than 666 mg of magnesium hydroxide  $[Mg(OH)_2]$  per g of the labeled amount of magaldrate is found.

**Aluminum hydroxide content**—

*Edetate disodium titrant*—Prepare and standardize as directed in the [Assay](#) under [Ammonium Alum](#).

*Test preparation*—Prepare as directed in the test for [Magnesium hydroxide content](#).

*Procedure*—Transfer 10.0 mL of *Test preparation* and 20 mL of water to a 250-mL beaker, and proceed as directed for [Procedure](#) in the test for [Aluminum hydroxide content](#) under [Magaldrate](#), beginning with “Add, with stirring, 25.0 mL of *Edetate disodium titrant*.” Not less than 321 mg and not more than 459 mg of aluminum hydroxide  $[Al(OH)_3]$  per g of the labeled amount of magaldrate is found.

**Other requirements**—Evaporate a volume of Oral Suspension, equivalent to about 5 g of magaldrate, on a steam bath to dryness: the residue so obtained meets the requirements of the tests for [Arsenic](#) under [Magaldrate](#).

**Change to read:**

**Assay for magaldrate**—Transfer an accurately measured quantity of Oral Suspension, equivalent to about 3 g of magaldrate, to a beaker. Add 100.0 mL of 1 N hydrochloric acid VS, and mix, using a magnetic stirrer to achieve dissolution. Titrate the excess acid with 1 N sodium

hydroxide VS to a pH of 3.0, determined potentiometrically. Perform a blank determination (see ▲[Titrimetry \(541\)](#)▲ (CN 1-Aug-2024) ). Each mL of 1 N hydrochloric acid is equivalent to 35.40 mg of magaldrate [Al<sub>5</sub>Mg<sub>10</sub>(OH)<sub>31</sub>(SO<sub>4</sub>)<sub>2</sub>].

**Assay for polydimethylsiloxane**—Transfer an accurately measured quantity of Oral Suspension, equivalent to about 250 mg of simethicone, to a 200-mL centrifuge bottle. Add an equal volume of hydrochloric acid, swirl to dissolve the Oral Suspension, add 25.0 mL of hexanes, and immediately close the bottle securely with a cap having an inert liner. Shake the bottle for 30 minutes, and centrifuge the mixture until a clear supernatant layer is obtained (*Assay preparation*). Prepare a *Standard preparation* of [USP Polydimethylsiloxane RS](#) in hexanes having a known concentration of about 10 mg per mL. Concomitantly determine the absorbances of the *Assay preparation* and the *Standard preparation* in 0.1-mm cells at the wavelength of maximum absorbance at about 7.9 μm and at the wavelengths of minimum absorbance at about 7.5 μm and 8.3 μm, with a suitable IR spectrophotometer, using hexanes as the blank. Draw a linear baseline between the two minima, and determine the absorbances for the *Standard preparation* and the *Assay preparation* with respect to the baseline, making any necessary correction for the blank. Calculate the quantity, in mg, of [–(CH<sub>3</sub>)<sub>2</sub>SiO–]<sub>n</sub> in the portion of Oral Suspension taken by the formula:

$$25C(A_u/A_s)$$

in which C is the concentration, in mg per mL, of [USP Polydimethylsiloxane RS](#) in the *Standard preparation*; and A<sub>u</sub> and A<sub>s</sub> are the absorbances of the *Assay preparation* and the *Standard preparation*, respectively.

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MAGALDRATE AND SIMETHICONE ORAL SUSPENSION	<a href="#">Documentary Standards Support</a>	SM32020 Small Molecules 3

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. 50(1)

**Current DocID:** GUID-D5D9EEE9-ADE7-4D1B-B568-DC0AD179C932\_5\_en-US

**DOI:** <https://doi.org/10.31003/USPNF.M46470.05.01>

**DOI ref:** [p3mdl](#)